Roger Baxter1, Yaela Baine, Devayani Kolhe, Carmen I Baccarini, Jacqueline M Miller, Marie Van der Wielen. 1. From the *Kaiser Permanente Vaccine Study Center, Oakland, California; †Vaccines Discovery & Development, GSK Vaccines, King of Prussia, Pennsylvania; †Pharma Europe & EMAP, GSK Pharmaceuticals India Ltd, Bangalore, India; and §Clinical R&D, GSK Vaccines, Wavre, Belgium.
Abstract
BACKGROUND: We evaluated antibody persistence after 1 dose of meningococcal serogroupsACWY tetanus toxoid (MenACWY-TT) or diphtheria toxoid (MenACWY-DT) conjugate vaccines and subsequent booster responses to MenACWY-TT. METHODS: In the initial phase II, open, multicenter study (NCT00454909), 872 participants aged 10-25 years received1 MenACWY-TT or MenACWY-DT dose. In this study (NCT00715910), antibody persistence was evaluated at years 1, 3 and 5 by serum bactericidal activity assays using human complement (hSBA). At year 5, all participants received a MenACWY-TT booster dose. Immune responses at 1-month postbooster were compared with a control group including 101 participants aged 15-30 years who received a primary MenACWY-TT dose. Solicited and unsolicited adverse events were recorded for 4 and 31 days, respectively, followed by a 6-month extended safety follow-up. RESULTS: At year 5, ≥79.5% of MenACWY-TT-primed (n = 170) and MenACWY-DT-primed (n = 45) participants had hSBA titers ≥1:8 for MenC, MenW and MenY, and ≥37.5% for MenA. For all serogroups, ≥85.7% and ≥67.1% of MenACWY-TT booster and primary dose recipients exhibited vaccine responses 1-month postmvaccination, respectively. Geometric mean titers were potentially higher in primed versus naive participants, with no potential difference between MenACWY-TT-primed and MenACWY-DT-primed participants (exploratory analyses). MenACWY-TT had a clinically acceptable safety profile. CONCLUSIONS: Before the booster dose administration at year 5, hSBA-MenC, -MenW and -MenY antibody persistence was observed in most participants. However, only ≥37.5% of MenACWY-TT and 44.4% of MenACWY-DT recipients retained hSBA-MenA titers ≥1:8. MenACWY-TT booster doses elicited robust anamnestic responses, irrespective of the priming vaccine, and were well tolerated.
RCT Entities:
BACKGROUND: We evaluated antibody persistence after 1 dose of meningococcal serogroups ACWY tetanus toxoid (MenACWY-TT) or diphtheria toxoid (MenACWY-DT) conjugate vaccines and subsequent booster responses to MenACWY-TT. METHODS: In the initial phase II, open, multicenter study (NCT00454909), 872 participants aged 10-25 years received 1 MenACWY-TT or MenACWY-DT dose. In this study (NCT00715910), antibody persistence was evaluated at years 1, 3 and 5 by serum bactericidal activity assays using human complement (hSBA). At year 5, all participants received a MenACWY-TT booster dose. Immune responses at 1-month postbooster were compared with a control group including 101 participants aged 15-30 years who received a primary MenACWY-TT dose. Solicited and unsolicited adverse events were recorded for 4 and 31 days, respectively, followed by a 6-month extended safety follow-up. RESULTS: At year 5, ≥79.5% of MenACWY-TT-primed (n = 170) and MenACWY-DT-primed (n = 45) participants had hSBA titers ≥1:8 for MenC, MenW and MenY, and ≥37.5% for MenA. For all serogroups, ≥85.7% and ≥67.1% of MenACWY-TT booster and primary dose recipients exhibited vaccine responses 1-month postmvaccination, respectively. Geometric mean titers were potentially higher in primed versus naive participants, with no potential difference between MenACWY-TT-primed and MenACWY-DT-primed participants (exploratory analyses). MenACWY-TT had a clinically acceptable safety profile. CONCLUSIONS: Before the booster dose administration at year 5, hSBA-MenC, -MenW and -MenY antibody persistence was observed in most participants. However, only ≥37.5% of MenACWY-TT and 44.4% of MenACWY-DT recipients retained hSBA-MenA titers ≥1:8. MenACWY-TT booster doses elicited robust anamnestic responses, irrespective of the priming vaccine, and were well tolerated.
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25
Authors: Charissa Fay Corazon Borja-Tabora; Paula Peyrani; Chris Webber; Marie Van der Wielen; Brigitte Cheuvart; Nathalie De Schrevel; Veronique Bianco; Emmanuel Aris; Mark Cutler; Ping Li; John L Perez Journal: BMC Infect Dis Date: 2020-06-18 Impact factor: 3.090
Authors: Beatriz Quiambao; Paula Peyrani; Ping Li; Mark W Cutler; Marie Van Der Wielen; John L Perez; Chris Webber Journal: Hum Vaccin Immunother Date: 2020-05-13 Impact factor: 3.452
Authors: S V Watle; D A Caugant; G Tunheim; T Bekkevold; I Laake; O B Brynildsrud; L M Næss Journal: Epidemiol Infect Date: 2020-03-31 Impact factor: 2.451
Authors: Milou Ohm; Debbie M van Rooijen; Axel A Bonačić Marinović; Mariëtte B van Ravenhorst; Marieke van der Heiden; Anne-Marie Buisman; Elisabeth A M Sanders; Guy A M Berbers Journal: Vaccines (Basel) Date: 2020-10-25